In this week’s edition of Innovationrx, we look at the accumulation of Eli Lilly weight loss pills, scaling the production of stem cells, the explosion of growing measles in Texas, and more. To get it in your box, Sign up here.
gettin
OfLi Lilly It is accumulating massive amounts of an oral weight for weight loss that is at least one year from the beginning, with the total “inventory before start” of nearly $ 550 million on December 31, 2024, according past.
Unusual movement represents a massive bet on a new pill once a day for weight loss called Orthglipron, at a time when Lilly GLP-1 drugs and its Novo Nordisk competitor have taken the market from the storm. Lilly’s Tirzepatide’s drugs, Zepbound for Overweight and Mounjaro for Diabetes, both administered by injection, make up $ 5.4 billion in revenue only in the fourth quarter.
ORFORGLPRON showed good results in a Phase 2 trial published in New England Journal of Medicine in June 2023. The highest dose of drugs resulted in 14.7% weight loss after 36 weeks for people who were stupid or overweight. Lilly has begun phase 3 research, and CEO Dave Ricks said last month that the drug could receive the approval of FDA from next year.
“The level of excitement here is high,” said Patrick Jonsson, Health Health’s Lilly president stale In an interview at the JP Morgan Health Care Conference in January. “This can potentially be the change of play when it comes to reaching more patients across the globe.”
Oral medications, after all, do not require the storage and transport of the cold chain that injections, and they are less complicated to produce. They are also more attractive to patients, especially those who have a needle phobia.
What does the easiest output and distribution for the price of the OROFORGLPROPER PRICE When the market hits remains to be seen. On Tuesday, Lilly began selling higher doses of Zepbound in the SH.BA with a discount of $ 150 compared to injector pen versions, Reuters reported. Then, on Wednesday, she said she would invest $ 27 billion in four new US manufacturing plants.
Research firm Insights Market Insights estimates the Global GLP-1 market at $ 25 billion in 2024 and predicts it will exceed $ 55.7 billion by 2031.
Cellino Inks an arrangement to build a source of stem cells in the General Mass
CEO Celino Nabiha Saklayen
Celo
Bubbleor more than a decadeBiotechnical researchers have explored the possibility of regeneration of damaged body parts as a way to treat degenerative diseases such as Parkinson and type 1 diabetes. One of the most promising technologies to do so are induced pluripotent cells (IPSC) , which can be programmed to be essentially any type of cell.
Catching: Making these cells is an intense work process that can cost millions of dollars to produce tissue for only one patient. Biotech Startup Cellino, united in 2017 by CEO and stale 30 below 30 Alumna Nabhiha Saklayen, is now a step closer to the IPSC output scale. It is building its first Massachusetts Gener Gene and the Massachusetts cell therapy institute. Cellino has raised a total of $ 100 million in entrepreneurship funds in a $ 140 million estimate since January 2022, according to Pitchbooks.
The folder will use the automated systems that Cellino has developed (read more about technology here) to generate IPSC from the blood of patients or skin cells in the country. The company estimates that the use of the smelter, which is set to go online next year, can reduce costs by a ten factor. Most importantly, an escalating, sustainable process will make it easier to produce new treatments that can go through the clinical test process and eventually commercialize, said CEO Sakaylen stale.
“With high quality cells, we can start to see what is reading to patients and know how powerful the medicine is,” she said. “This is difficult to show if the production is not standardized. So this is what I am really excited.”
Bioteknika and Pharma
Last December, FDA approti Ryoncil of the Mesoblast drug, which is the first time that a mesencal stromal cell (MSC) has received a green light from the agency. MSC are increased stem cells found in bone marrow that can be transformed into different types of cells. Ryoncil is used to treat children with severe grafting-wrapped disease (GVH) after a transplantation of stem cells, which is typical for patients with leukemia. Also also the first approved treatment for children with this disease that does not respond to steroids.
Said CEO of Mesoblast Silviu Itescu stale Last week the company plans to start trade sales of the drug this quarter, with the remaining obstacles setting prices with payers and the hospital transport product. “We have inventory for at least the next two years for children with acute GVH,” he said. The company is also pursuing clinical evidence for adults with GVH, as well as the use of its source cell products for children with serious Crohn disease, he said.
The shares of the company publicly traded have been reduced by 21% so far this year, with the last $ 16.
Digital health and he
The beginning of that biotech genesis Therapeutics entered a deal with the Incyte pharmaceutical company to use the drug detection platform, Gems, to detect small drug candidates with molecule against the three undiscovered objectives. Under the terms of the agreement, Incyte will pay its origin $ 30 million ahead and up to $ 295 million in other milestones and payments during the course of cooperation, plus royalties. Incyte, which has a $ 14 billion market cap, focuses on oncology, immunology and dermatology and other unfulfilled needs. This is the third agreement on its origin since September, after similar collaborations with Gilead Pharmaceutical Company and the Powerhouse Nvidia.
“We found that it was a really natural adaptation to combine gems and its ability to dagger challenging objectives with some of the needs Incyte had for some of its pipeline programs,” said Genesis CEO Evan Feinberg staleadding that another reason he wanted to work with Incyte is “his record of pioneers completely new medical areas”.
Flawed
Medtronic medical equipment manufacturer ($ 116 billion market) gained FDA approval for a new self-regulated deep brain stimulation for people with Parkinson’s disease, a disorder of the nervous system that affects movement. The adaptive device of brainense works similarly to a cardiac cardiac, but for the brain, using a surgically implanted neurostimulator to transmit electrical signals to specific areas of the disease affected by the disease. Medtronic said that approval was the first for an adaptive deep brain stimulation device for Parkinson, and that it would be the largest participation of a brain computer interface technology. About 1 million people in the US have been diagnosed with bad neurological disorder.
Public health and hospitals
Measles continues to spread to West Texas. There are now 124 confirmed cases, most of them in West Texas where the explosion began. The West Texas explosion is the largest the state has seen in 30 years, and highlights the difficulties that persuade people to receive vaccines in the current environment. A first death from the disease was reported Wednesday morning. A special, potentially connected explosion of measles in New Mexico has now increased in nine cases. The explosion also prompted parents who had not previously chosen children not to vaccinate to change their minds.
PLUS: HEALTH CARE EMPLOYMENT Unicorn unbelievable health is expanding from nurses to technique, a workforce that accounts for 60% of all health care workers and is now facing absence. Starting in San Francisco will also go beyond hospitals in home health organizations and outpatient care centers. Incredible Health, an alum to the next 2021 billion-dollar forbes starting, has placed more than 1 million nurses in 1,500 hospitals across the country from the beginning York and Texas, and plans to complete the national end up to end of the year.
Week deal
Eikon Therapeutics, who is developing a drug pipeline to treat cancer, announced it has raised $ 350 million, bringing its total funds to more than $ 1.1 billion. The Hayward -based Caliph -based company, worth $ 3.7 billion before the latest investment, according to Pitchbook, refused to unravel its new rating. Eikon plans to use new funds to support the continuous development of its candidates for drugs, which aim for advanced melanoma, as well as brain, ovary, breast, prostate and pancreatic cancer. To facilitate its development of medication, the company uses its advanced technology of fluorescent microscopy, which enables it to observe how different substances interact at real time cellular level. Eicon’s general manager, Roger Perlmutter was the head of R&D in Merck.
What are we reading
A newly discovered nude coronavirus has the potential to pour into humans using the same pathway as the virus that causes Covid-19.
The general director of billionaire Colossal biosciences Ben Lamm sees uses for human health in efforts to revitalize wool mom.
At least three DOGE employees have access to the systems of the National Institute of Health that control finances, budget and procurement.
How millions of Dr. Oz with Medicare, including as a ruthless promoter of Medicare Medicare’s Medicare Advantage advantage for elderly Americans.
FDA reopen staff in its division of medical equipment after mass holidays by Elon Musk’s Doge. Meanwhile, the new administrator responsible for the FDA food sharing seems to have no significant experience beyond hunting with Donald Trump Jr.
The bird’s flu wiped the Long Island Duck Duck to Doug Corwin’s Duck, forcing him to pull all 100,000 flocks.
Two people, one in Wyoming and one in Ohio, are hospitalized with bird flu.
New research reveals that hormone therapy significantly improves the emotional health of young transgender people.
Workers at the Health Clinic collect constitutional protection for their patients as immigration raids approach.
Trump signed an executive order to strengthen the rules for the transparency of the health care cost previously adopted by Trump and Biden administrations.
More by Forbes